Key facts
- Cagent Vascular’s last known valuation is $80.7M (Jan 2024).
- It has raised $73.2M across 5 recorded rounds; the latest was Early Stage VC ($24.5M) in May 2026.
- Notable investors include Ben Franklin Technology Partners of Southeastern Pennsylvania, BF Belmont, Balestier Investments, Blue Ridge Medical., M&L Group — 10 tracked in total.
- Cagent Vascular has filed 7 Form Ds with the SEC since 2014, most recently Jun 2026 ($24.5M sold to 51 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Cagent Vascular
Funding rounds
5 roundsAbout Cagent Vascular
Developer of an intravascular technology designed to treat diseased peripheral arteries. The company's technology is a minimally invasive device for vessel dilatation in cardiovascular disease interventions with multiple longitudinal lines of interrupted micro-serrations used for arterial expansion along those lines, enabling healthcare providers to improve the lives of patients.
- Sector
- Healthcare
- HQ
- Wayne, PA, United States
- Founded
- 2014
- Employees
- 78
- Website
- cagentvascular.com/
- Ownership
- Privately Held (backing)
Cagent Vascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cagent Vascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cagent Vascular in its N-PORT filings yet. We sweep new filings monthly.